Sinovac Biotech Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Sinovac Biotech Ltd with three other
companies in this sector in China:
Lionco Pharmaceutical Group Co Ltd
sales of 478.59 million Chinese Renmimbi [US$74.35 million]
of which 100%
Furen Pharmaceutical Group Industry Co Ltd
(495.63 million Chinese Renmimbi [US$77.00 million]
of which 95%
was Pharmaceutical Industry), and
Honz Pharmaceutical Co Ltd
(471.46 million Chinese Renmimbi [US$73.24 million]
of which 100%
was Medical Industry).
During the year ended December of 2016, sales at
Sinovac Biotech Ltd were 481.91 million Chinese Renmimbi (US$74.86 million).
increase of 13.7%
versus 2015, when the company's sales were 423.91 million Chinese Renmimbi.
Sales of H5n1 saw an increase
that was more than double the company's growth rate: sales were up
75.5% in 2016, from
24.22 million Chinese Renmimbi to 42.51 million Chinese Renmimbi.
Not all segments of Sinovac Biotech Ltd experienced an increase in sales in 2016:
sales of Mumps fell 65.7% to 3.17 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Sinovac Biotech Ltd also experienced decreases in sales in
Inactivated Hepatitis Vaccines (down 55.9% to 137.03 million Chinese Renmimbi)
Influenza Vaccines (down 17.9% to 65.40 million Chinese Renmimbi)